E. Spaeth

发表

Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?

M. Andreeff, F. Marini, A. Klopp, 2010, Stem cells.

Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells

M. Andreeff, F. Marini, A. Klopp, 2008, Gene Therapy.

Tracking inflammation-induced mobilization of mesenchymal stem cells.

F. Marini, E. Spaeth, S. Kidd, 2012, Methods in molecular biology.

Origins of the Tumor Microenvironment: Quantitative Assessment of Adipose-Derived and Bone Marrow–Derived Stroma

M. Andreeff, J. Burks, F. Marini, 2012, PloS one.

ELUCIDATING THE ROLE OF CD44 EXPRESSION ON MESENCHYMAL STEM CELLS WITHIN THE TUMOR MICROENVIRONMENT

E. Spaeth, Erika L Spaeth, 2010 .

The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo

M. Konopleva, M. Andreeff, Weiguo Zhang, 2013, PloS one.

The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe.

M. Andreeff, F. Marini, A. Klopp, 2008, Cytotherapy.

Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment.

M. Andreeff, B. Toole, F. Marini, 2013, Cancer research.

Mesenchymal Stem/Stromal Cells as Cellular Vehicles for Tumor Targeting

M. Andreeff, F. Marini, A. Klopp, 2010 .

mediates chemoresistance B κ Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-

R. Davis, M. Konopleva, E. Shpall, 2014 .

Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment.

W. Woodward, M. Andreeff, J. Cox, 2007, Cancer research.

Dissecting mesenchymal stem cell movement: migration assays for tracing and deducing cell migration.

F. Marini, E. Spaeth, Erika L Spaeth, 2011, Methods in molecular biology.

Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells

J. Fueyo, C. Gomez-Manzano, F. Marini, 2010, Cancer Gene Therapy.

Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

Stephen T. C. Wong, P. Ram, A. Sood, 2018, Cancer research.

Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment.

M. Konopleva, M. Andreeff, I. Samudio, 2010, Cytotherapy.

Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging

M. Andreeff, F. Marini, A. Klopp, 2009, Stem cells.

Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.

G. Hortobagyi, M. Andreeff, A. Sahin, 2012, The Journal of clinical investigation.

Coinfection of Chlamydia trachomatis, Ureaplasma urealyticum and human papillomavirus among patients attending STD clinics in Estonia

M. Ustav, E. Spaeth, T. Talpsep, 2007, Scandinavian journal of infectious diseases.

Mesenchymal Stem Cell Transition to Tumor-Associated Stromal Cells Contributes to Cancer Progression

F. Marini, E. Spaeth, K. Bussard, 2016 .

Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression

A. Kate Sasser, Brett Hall, Keri Watson, 2009, PloS one.

MSCs in Solid Tumors and Hematological Malignancies: From Basic Biology to Therapeutic Applications

M. Andreeff, F. Marini, E. Spaeth, 2013 .

Mesenchymal Stem/Stromal Cell-Targeted Therapies for Solid Tumors and Hematological Malignancies

M. Andreeff, F. Marini, E. Spaeth, 2015 .

Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells

W. Woodward, T. Buchholz, M. Andreeff, 2010, PloS one.

A combined clinical and genetic model for predicting risk of ovarian cancer

G. Dite, R. Allman, E. Spaeth, 2022, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

A streamlined model for use in clinical breast cancer risk assessment maintains predictive power and is further improved with inclusion of a polygenic risk score

J. Hopper, R. Allman, E. Spaeth, 2021, PloS one.

Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.

R. Davis, D. Strunk, M. Konopleva, 2014, Blood.

Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.

M. Andreeff, I. Samudio, K. Roby, 2013, Cytotherapy.

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

C. Creighton, Z. Estrov, D. Harris, 2016, The Journal of experimental medicine.

Quantitative multispectral analysis following fluorescent tissue transplant for visualization of cell origins, types, and interactions.

F. Marini, E. Spaeth, C. Booth, 2013, Journal of visualized experiments : JoVE.

Bridging the Data Gap in Breast Cancer Risk Assessment to Enable Widespread Clinical Implementation across the Multiethnic Landscape of the US

R. Allman, E. Spaeth, A. Starlard-Davenport, 2018, Journal of cancer treatment & diagnosis.

Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk

G. Dite, R. Allman, E. Spaeth, 2023, The Prostate.

Melanoma risk prediction based on a polygenic risk score and clinical risk factors

G. Dite, R. Allman, E. Spaeth, 2023, Melanoma research.

Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk

G. Dite, R. Allman, E. Spaeth, 2023, Breast Cancer Research and Treatment.